|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 950 F Street, NW |
Address2 | Suite 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31350-12
|
||||||||
|
6. House ID# 306540000
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Paul J. Larsen, Deputy Compliance Officer & Assistant General Counsel |
Date | 01/20/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 3082, Continuing Appropriations Amendments, 2011: FDA funding, comparative effectiveness funding, importation policy rider, Biomedical Advanced Research and Development Authority (BARDA), trade and intellectual property restrictions, patent settlements
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
David |
Boyer |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Andrea |
Douglas |
|
|
|
Lea |
Fisher |
|
|
|
Valerie |
Jewett |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Matt |
Sulkala |
|
|
|
Steve |
Tilton |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 573, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions
H.R. 628, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program
H.R. 1260, Patent Reform Act of 2009: reforms of the patent laws
H.R. 1706, Protecting Consumer Access to Generic Drugs Act of 2009: patent settlements
H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: patent term restoration filing deadlines and tax issues
H.R. 4899, Supplemental Appropriations Act, 2010: patent settlements
H.R. 4954, To amend title 35, United States Code, to provide recourse under the patent law for persons who suffer competitive injury as a result of false markings: false patent marking
H.R. 5980, Bring Jobs Back to America: Strategic Manufacturing & Job Repatriation Act: publication of patent applications and the economy
H.R. 6352, Patent Lawsuit Reform Act of 2010: false patent marking
H.R. 5322, Patent and Trademark Office Funding Stabilization Act of 2010: Patent and Trademark Office Funding
S. 299, To establish a pilot program in certain United States district courts to encourage enhancement of expertise in patent cases among district judges: patent pilot program
S. 369, Preserve Access to Affordable Generics Act: patent settlements
S. 501, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: authorized generic drug provisions
S. 515, Patent Reform Act of 2009: reforms of the patent laws
S. 610, Patent Reform Act of 2009: reforms of the patent laws
S. 1315, Drug Price Competition Act of 2009: 180-day exclusivity issues
S. 3677, Financial Services and General Government Appropriations Act, 2011: patent settlements
International intellectual property policy issues
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Commerce - Dept of (DOC), Patent & Trademark Office (PTO), White House Office, Executive Office of the President (EOP), Office of Management & Budget (OMB), U.S. Trade Representative (USTR), Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Boyer |
|
|
|
John |
Castellani |
|
|
|
Lea |
Fisher |
|
|
|
Bryant |
Hall |
|
|
|
David |
Korn |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Anne |
Pritchett |
|
|
|
Richard |
Smith |
|
|
|
Matt |
Sulkala |
|
|
|
Steve |
Tilton |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 422, Heart Disease Education, Analysis Research, and Treatment for Women Act: R&D tax credit provisions
H.R. 1032, Heart Disease Education, Analysis Research, and Treatment for Women Act: clinical trial data reporting issues
H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness
H.R. 2751, FDA Food Safety Modernization Act: importation
H.R. 2824, Doctor-Patient Relationship and Research Protection Act: comparative effectiveness
H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, 340B program issues, health reform fee, Independent Payment Advisory Board (IPAB) and other health reform implementation issues
H.R. 4213, American Jobs and Closing Tax Loopholes Act of 2010: 340B program issues
H.R. 4489, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act: transparency of drug pricing
H.R. 4872, Health Care and Education Reconciliation Act of 2010: health reform fee issues
H.R. 4994, Medicare and Medicaid Extenders Act of 2010: 340B program and other health care issues
H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010: controlled substance monitoring
H.R. 5809, Safe Drug Disposal Act of 2010: disposal of controlled substances
S. 510, FDA Food Safety Modernization Act: importation
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
S. 1203, Grow Research Opportunities With Taxcredits' Help Act: R&D tax credit provisions
S. 1213, Patient-Centered Outcomes Research Act of 2009: comparative effectiveness
S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation
S. 1679, Affordable Health Choices Act: importation, and other health reform implementation issues
S. 3397, Secure and Responsible Drug Disposal Act of 2010: disposal of controlled substances
General FDA advocacy
Biopharmaceutical innovation policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Executive Office of the President (EOP), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA), Treasury - Dept of, Internal Revenue Service (IRS), Commerce - Dept of (DOC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
David |
Boyer |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Andrea |
Douglas |
|
|
|
Daniel |
Durham |
|
|
|
Lea |
Fisher |
|
|
|
Bryant |
Hall |
|
|
|
Valerie |
Jewett |
|
|
|
Ann |
Kaplan |
|
|
|
Hallie |
Maranchick |
|
|
|
Kendra |
Martello |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Anne |
Pritchett |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Heather |
Strawn |
|
|
|
Matt |
Sulkala |
|
|
|
Jennifer |
Swenson |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 3590, Patient Protection and Affordable Care Act: comparative effectiveness, Part D coverage gap discounts, Part D issues generally, Medicare payment issues including the Independent Payment Advisory Board (IPAB), and Medicaid issues
H.R. 4752, Medicare Prescription Drug Price Negotiation Act of 2010: non-interference provisions
H.R. 4872, Health Care and Education Reconciliation Act of 2010: Part D coverage gap discounts, Part D issues generally, Medicaid rebate issues, health reform fee, and other health reform implementation issues generally
H.R. 4994: Medicare and Medicaid Extenders Act of 2010: exclusion issues
H.R. 6130 Strengthening Medicare Anti-Fraud Measures Act of 2010: exclusion issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, White House Office, Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maya |
Bermingham |
|
|
|
David |
Boyer |
|
|
|
Randy |
Burkholder |
|
|
|
John |
Castellani |
|
|
|
Andrea |
Douglas |
|
|
|
Daniel |
Durham |
|
|
|
Lea |
Fisher |
|
|
|
Gregory |
Gierer |
|
|
|
Bryant |
Hall |
|
|
|
Valerie |
Jewett |
|
|
|
Ann |
Kaplan |
|
|
|
Thomas |
Moore |
|
|
|
Brian |
Nagle |
|
|
|
Lori |
Reilly |
|
|
|
Richard |
Smith |
|
|
|
Heather |
Strawn |
|
|
|
Matt |
Sulkala |
|
|
|
Jennifer |
Swenson |
|
|
|
Steve |
Tilton |
|
|
|
Chester (Chip) |
Davis |
Jr |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3012, Trade Reform, Accountability, Development, and Employment Act of 2009 (TRADE Act of 2009): trade agreements
Korea Free Trade Agreement: intellectual property, market access and public health
Trans-Pacific Strategic Economic Partnership Agreement (TPP): intellectual property issues
Special 301 submission
Preference Program Reform
International market access and intellectual property issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR), Commerce - Dept of (DOC), State - Dept of (DOS), White House Office,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
John |
Castellani |
|
|
|
Lea |
Fisher |
|
|
|
David |
Korn |
|
|
|
Matt |
Sulkala |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address: http://www.phrma.org/about_phrma/member_company_list/members
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |